CG Oncology, Inc.
Records under this name other than the patents CG Oncology, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,473,418 | Pan cancer oncolytic vectors and methods of use thereof Term ended Term ended Mar 9, 2025 · USPTO record | Term ended | Term ended Mar 9, 2025 | USPTO record |
| US 7,858,083 | Pan Cancer Oncolytic Vectors and Methods of Use Thereof Term ended Ended no later than Mar 9, 2025 · Low confidence | Term ended | Ended no later than Mar 9, 2025 | Low confidence |
| US 7,459,154 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium Term ended Term ended Sep 15, 2023 · USPTO record | Term ended | Term ended Sep 15, 2023 | USPTO record |
| US 7,267,815 | Methods and reagents for the enhancement of virus transduction in the bladder epithelium Term ended Term ended Mar 18, 2023 · USPTO record | Term ended | Term ended Mar 18, 2023 | USPTO record |
| US 7,968,333 | Adenovirus vectors containing cell status-specific response elements and methods of use thereof Term ended Term ended Sep 18, 2021 · USPTO record | Term ended | Term ended Sep 18, 2021 | USPTO record |
| US 6,692,736 | Cell-specific adenovirus vectors comprising an internal ribosome entry site Term ended Term ended Jul 16, 2021 · USPTO record | Term ended | Term ended Jul 16, 2021 | USPTO record |
| US 6,991,935 | Target cell-specific adenoviral vectors containing E3 and methods of use thereof Term ended Term ended Aug 7, 2020 · USPTO record | Term ended | Term ended Aug 7, 2020 | USPTO record |
| US 6,495,130 | Target cell-specific adenoviral vectors containing E3 and methods of use thereof Term ended Ended no later than Dec 29, 2019 · USPTO record | Term ended | Ended no later than Dec 29, 2019 | USPTO record |
| US 7,575,919 | Adenovirus vectors containing cell status-specific response elements and methods of use thereof Term ended Ended no later than Sep 9, 2019 · USPTO record | Term ended | Ended no later than Sep 9, 2019 | USPTO record |
| US RE42,373 | Adenovirus vectors containing cell status-specific response elements and methods of use thereof Term ended Ended no later than Sep 9, 2019 · USPTO record | Term ended | Ended no later than Sep 9, 2019 | USPTO record |